Prognostic gene mutations and distinct gene-and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8
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Trisomy 8 ( þ 8) is the most frequent numerical chromosome aberration in acute myeloid leukemia (AML), occurring in B9% of adult patients. 1 In one-third of such patients, þ 8 is the sole cytogenetic abnormality. 1 These patients are mostly classified as having an intermediate prognosis. 1, 2 The few available studies suggest that sole þ 8 AML is molecularly heterogeneous, [3] [4] [5] but the clinical impact of mutations remains to be established. Moreover, although the biologic features of sole þ 8 AML have been investigated using genome-wide gene- 6, 7 or microRNAexpression 8 analyses, these studies included small numbers of patients.
We report herein the molecular and clinical characterization of 80 adults with de novo AML and sole þ 8 enrolled on Cancer and Leukemia Group B/Alliance clinical trials. Methodological details are described in the Supplementary Information.
Ninety-four percent of the sole þ 8 AML patients harbored at least one mutation (Supplementary Figure S1 ). The most frequently mutated genes were RUNX1 (32%), ASXL1 (29%), FLT3 (specifically FLT3-ITD: 29%), IDH2 (26%), DNMT3A (25%) and NPM1 (22.5%) ( Table 1) . Younger (o60 years) patients less often harbored mutations in RUNX1 (P ¼ 0.008), ASXL1 (P ¼ 0.002), IDH2 (P ¼ 0.04) and TET2 (P ¼ 0.001) than older (X60 years) patients.
We compared the mutational features of the þ 8 AML cohort with CN-AML patients, the largest and molecularly best characterized cytogenetic subset of AML.
1,2 Among younger and older patients, those with sole þ 8 more often had mutations in ASXL1 (younger, P ¼ 0.04; older, Po0.001) and RUNX1 (younger, P ¼ 0.08; older, Po0.001) and less often in NPM1 (younger and older, Po0.001) (Supplementary Table S1 ). Younger sole þ 8 patients also less frequently had TET2 (P ¼ 0.002) and CEBPA (P ¼ 0.005) mutations than CN-AML patients. Hence, particularly mutations in ASXL1 and RUNX1 associate with sole þ 8 AML. However, no single mutation was as tightly associated with þ 8 AML as reported for AML with other numeric aberrations, for example, þ 11 and MLL-PTD, 9 þ 13 and RUNX1 mutations. 10 Future studies may determine whether þ 8 favors acquisition of RUNX1 and ASXL1 mutations or whether CN-AML with such mutations is prone to the gain of þ 8.
Patients included in the outcome analyses received cytarabine/ daunorubicin-based induction and consolidation, and no allogeneic hematopoietic stem-cell transplantation in first complete remission (CR) (Supplementary Table S2 ). As in previous reports, 1 the outcomes of sole þ 8 AML patients were relatively poor; 64% achieved a CR and 5-year rates were 9% for disease-free survival (DFS) and 15% for overall survival (OS) ( Table 1) . Notably, there were no significant differences in CR rates, DFS or OS between younger and older patients (Table 1) , despite differences in treatment intensity. This is in contrast with the better outcomes of younger patients previously observed in CN-AML 2 and could be related to differences in the mutation or gene-expression patterns (described below) between the cytogenetic subsets.
To further characterize the outcome of sole þ 8 AML, we evaluated it in comparison with CN-AML and in the context of the European LeukemiaNet classification. 2 Among younger adults, sole þ 8 AML associated with worse CR rates (P ¼ 0.003), and shorter DFS (P ¼ 0.01) and OS (P ¼ 0.003) than CN-AML; among older individuals, sole þ 8 patients had only a trend for shorter DFS (P ¼ 0.09) (Supplementary Table S3 ). In the European LeukemiaNet recommendations, 2 the Intermediate-II Genetic Group consists of two subsets: patients with t(9;11)(p22;q23) and patients with cytogenetic aberrations not classified in the Favorable or Adverse Genetic Groups, which also include sole þ 8. Thus, we compared the outcome of sole þ 8 patients with that of t(9;11) patients and the remaining Intermediate-II patients (Supplementary Table S3 ). Among younger adults, sole þ 8 patients had shorter DFS (P ¼ 0.02) and OS (P ¼ 0.02) than t(9;11) patients, and worse CR rates (P ¼ 0.04) and OS (P ¼ 0.05) but no significant differences in DFS compared with the remaining Intermediate-II patients. Among older patients, there were no significant outcome differences between sole þ 8, t(9;11) and the remaining Intermediate-II patients.
It is currently unknown whether molecular markers allow risk stratification in sole þ 8 AML. Thus, we tested the prognostic significance of the various markers in multivariable models (Table 2) .
In younger patients, only BAALC expression impacted on CR attainment, with high BAALC expressers having lower odds of achieving a CR (P ¼ 0.04). FLT3-ITD status was the only variable associated with DFS; patients with FLT3-ITD had worse DFS than those without (P ¼ 0.054). Both harboring FLT3-ITD (P ¼ 0.02) and Accepted article preview online 21 March 2014; advance online publication, 15 April 2014 Letters to the Editor Table 1 . Pretreatment clinical and molecular characteristics and outcome of patients with de novo acute myeloid leukemia and sole þ 8 and comparison by age group (o60 years vs X60 years) The median expression value was used as a cut point. It was calculated based on the expression levels assessed by RT-PCR. d The median expression value was used as a cut point. It was calculated based on the expression levels on the Affymetrix array.
e Of the 80 patients, 59 were evaluable for outcome. Pretreatment clinical and molecular characteristics of the patients included in outcome analyses are provided in Supplementary Table S2. f Ratios are comparing outcome of patients o60 years vs X60 years.
Letters to the Editor being non-white (P ¼ 0.01) associated with worse OS. Patients with FLT3-ITD had almost three times higher risk of death than those without FLT3-ITD (Table 2) . At 5 years, FLT3-ITD-positive patients had a DFS rate of 0% and an OS rate of 7% compared with the respective 22% and 31% for patients without FLT3-ITD (DFS: P ¼ 0.054, OS: P ¼ 0.02; unadjusted rates; Supplementary Figure S2a , Supplementary Table S4) .
Among older patients, TET2 mutation status was the only significant marker for CR and DFS (Table 2 ). Only 38% of the TET2-mutated patients achieved a CR compared with 80% of wild-type TET2 patients (P ¼ 0.04), and the former had shorter DFS (P ¼ 0.048; Supplementary Table S4 ). Both TET2 mutations (P ¼ 0.003) and wild-type RAS (P ¼ 0.03) were associated with shorter OS (Table 2) . TET2-mutated patients had almost fourfold higher risk of death than those with wild-type TET2; the respective 3-year OS rates were 0 and 25% (P ¼ 0.004; unadjusted rates; Supplementary Figure S2b ; Supplementary Table S4 ). The patient numbers were too small to formally investigate the significance of the combined TET2 and RAS mutation status. However, three of the four older þ 8 patients with both wild-type TET2 and RAS mutation were alive 3 years after diagnosis, whereas no patient with mutated TET2 (and mostly wild-type RAS) was.
We previously reported that sole þ 8 AML associates with the overexpression of chromosome 8-located genes due to their higher genomic dosage, 6 and subsequent, small studies made similar observations. 7 The present study of a relatively large patient cohort further characterizes this finding. We compared the geneexpression profiles between sole þ 8 and CN-AML patients, and derived a signature comprising 452 genes significantly upregulated and 329 downregulated in þ 8 AML (Supplementary Table S5 ). Consistent with a gene dosage effect, 189 (42%) of the genes significantly upregulated in þ 8 AML were located on chromosome 8 (Supplementary Figure S3a) . Accordingly, in gene-set enrichment analyses of the chromosome locations of all genes studied, chromosome 8 exhibited marked upregulation in þ 8 AML compared with CN-AML (familywise error rate Po0.001; normalized enrichment score 16.15). In a leave-one-out cross-validated analysis, 399 (92%) of 434 patients were correctly classified as sole þ 8 or CN-AML based on the expression pattern of the chromosome 8-located genes of the signature (80.6% sensitivity to correctly predict the presence of þ 8, 94% specificity to correctly predict its absence). In line with our earlier analysis of 41 genes in 10 þ 8 AML patients, 6 the upregulation of genes mapped to chromosome 8 was evenly distributed along the entire chromosome (Supplementary Figure S3b) .
Among the most upregulated genes on chromosome 8 was BAALC. We originally identified BAALC because of its high expression in þ 8 AML and subsequently described its high expression as a prognostically adverse marker in CN-AML. 11 As detailed above, higher BAALC expression also associated with lower odds for CR attainment among younger sole þ 8 patients, despite its overall high expression in sole þ 8 AML. A genomic neighbor of BAALC, that is, FZD6 (receptor of the Wnt signaling cascade) was also highly expressed in þ 8 AML. Strongly upregulated in þ 8 AML, but located on chromosome 21, was APP (overexpressed in IDH2 R172-mutated CN-AML 12 and AML with amplification of 21q material 13 ). In gene ontology analyses of genes expressed X1.5-fold in sole þ 8 AML, significantly overrepresented terms were response to chemical stimulus and extracellular matrix organization (Supplementary Figure S4) . Among the downregulated genes were CD33 (target of gemtuzumab ozogamicin) and histone genes.
From the comparison of 354 mature microRNAs between sole þ 8 and CN-AML patients, we derived a signature of 7 microRNAs-5 upregulated and 2 downregulated in þ 8 AML (Supplementary Table S6 ). In contrast to the protein-coding genes, none of the chromosome 8-located microRNAs that we studied was significantly upregulated in þ 8 AML (Supplementary Table S7 ). Hence, it is currently uncertain whether microRNA expression is affected by genomic dosage in the same manner as gene expression. MicroRNAs overexpressed in þ 8 AML were miR-34b and miR-107 (activated by TP53), 14, 15 miR-370 (downregulates NF1, the deficiency of which causes hyperactive RAS signaling in myeloid neoplasms) 16 and miR-342 (upregulated by all-transretinoic acid in acute promyelocytic leukemia). 17 In summary, sole þ 8 AML is molecularly heterogeneous, with mutations in RUNX1, ASXL1, IDH2, DNMT3A and NPM1, and FLT3-ITD being the most frequent. Mutation frequencies differ between þ 8 AML and CN-AML, and between younger and older sole þ 8 patients, whereas the outcomes of younger and older sole þ 8 AML patients /l increase), WBC (50 Â 10 9 /l increase), race (white vs non-white), sex (male vs female) and extramedullary involvement (present vs absent); for OS, FLT3-ITD (positive vs negative), platelets (50 Â 10 9 /l increase), WBC (50 Â 10 9 /l increase), race (white vs non-white), sex (male vs female) and extramedullary involvement (present vs absent). In patients aged X60 years: for CR, TET2 (mutated vs wild type), RUNX1 (mutated vs wild type), ASXL1 (mutated vs wild type), miR-155 expression (high vs low), hemoglobin (continuous) and þ 8 metaphases in bone marrow (X80% vs o80%); for DFS, NPM1 (mutated vs wild type), FLT3-ITD (positive vs negative), TET2 (mutated vs wild type), and RAS (mutated vs wild type); for OS, TET2 (mutated vs wild type), IDH2 (mutated vs wild type), RAS (mutated vs wild type), miR-3151 expression (high vs low) and sex (male vs female).
are only slightly different. High BAALC expression and FLT3-ITD associated with worse outcomes among younger and TET2 mutations and wild-type RAS among older sole þ 8 AML patients. Moreover, sole þ 8 AML is characterized by distinct gene-and microRNAexpression patterns. The increased dosage of chromosome 8-located genes leads to their overexpression, an effect not observed for microRNAs. Our findings should be useful for the guidance of treatment decisions and the development of new therapies that improve the poor outcome of patients with sole þ 8 AML.
